Search PubMed⌕ Search

Biomedical subjects

M B Abelson

Publications and source records attributed to M B Abelson.

75 records · Page 5Linked to original sources

Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy.

The pathogenesis of ocular allergy involves multiple mechanisms, which lead to mast cell degranulation and the release of chemical mediators. Mast cell mediators that have been implicated in allergic ocular disease include histamine, eosinophil chemotactic factors, eosinophil granule major basic protein, platelet-activating factor, prostaglandin D2, and several other less well-defined preformed or newly synthesized mediators. The release of these chemical mediators ultimately results in conjunctival vasodilation, increased vascular permeability, leukocyte chemotaxis, and, rarely, ocular surface destruction. Current therapy of ocular allergy involves elimination of the offending allergen, modulation of the immune system, and pharmacologic inhibition of the chemical mediators. The purpose of this article is to provide a better understanding of the pathogenesis and current therapy of ocular allergic disorders and to review the central role of the mast cell and chemical mediators involved in ocular allergy.

Anti-Inflammatory Agents, Non-Steroidal↗

Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis.

Acute allergic conjunctivitis (AAC) is a common ocular allergic disorder and incident rates as high as 20% have been reported. Although a wide range of therapeutic agents are available for the treatment of AAC, the ideal treatment seems to have remained elusive. Levocabastine, a highly potent specific H1-receptor, appears to offer a promising alternative as a topical single-agent therapy. Levocabastine eye drops have been found to be well tolerated with an adverse-effect profile comparable to placebo and sodium cromoglycate. In addition, ocular levocabastine has been shown to have a rapid onset and long duration of action. The efficacy of levocabastine has been extensively investigated in conjunctival provocation tests and environmental studies. The available data suggest that ocular levocabastine is an effective therapeutic agent. Statistically significant differences in favour of levocabastine have been observed in comparisons with sodium cromoglycate, antazoline/naphazoline and oral terfenadine.

Acute Disease↗